Neurological-Focused Pharmaceutical Company, Lundbeck, Continues Use of Medidata Clinical Cloud With Multi-Year Partnership

NEW YORK and COPENHAGEN-October 5, 2017-Medidata (NASDAQ: MDSO), a global provider of cloud-based solutions and data analytics for clinical research, today announced that pharmaceutical firm H. Lundbeck A/S (Lundbeck), has entered a multi-year partnership to continue its use of the Medidata Clinical Cloud® and utilize operational capabilities to power their next generation global clinical trials.   The continued partnership allows Lundbeck to leverage integral parts of the Medidata Clinical Cloud platform that provide key capabilities in study conduct and site support, including Medidata Rave®, Coder®, and TSDV (Targeted Source Document Verification).   A Medidata customer since 2007, Lundbeck is a global pharmaceutical company specializing in psychiatric and neurological disorders. By continuing its use of Medidata Rave®, a industry solution for capturing, managing, and reporting data, Coder®, and TSDV (Targeted Source Document Verification), Lundbeck will increase the quality of its clinical research efforts by more accurately evaluating clinical data, streamlining workflows, and ultimately, optimizing trial results.   “We’re proud to be a long term partner to Lundbeck, an innovative organization bringing together deep industry expertise in drug development activities for neurological disorders,” said Mike Capone, chief operating officer at Medidata. “We look forward to continuing to power their mission to tackle unmet needs for patients living with serious medical conditions.”  

About Medidata

Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers-from study design and planning through execution, management and reporting.   Medidata Contacts Investor: Anthony D’Amico, Medidata Solutions, +1 732-767-4331, 

adamico@mdsol.com

Media: Erik Snider, Medidata Solutions, +1 646-362-2997, 

esnider@mdsol.com